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A B S T R A C T
Purpose
Apart from rare pedigrees with multiple cases of acute myeloid leukemia (AML), there is limited
data on familial aggregation of AML and myelodysplastic syndromes (MDSs) in the population.
Patients and Methods
Swedish population-based registry data were used to evaluate risk of AML, MDS, and other
malignancies among 24,573 first-degree relatives of 6,962 patients with AML and 1,388 patients
with MDS compared with 106,224 first-degree relatives of matched controls. We used a marginal
survival model to calculate familial aggregation.
Results
AML and/or MDS did not aggregate significantly in relatives of patients with AML. There was a
modest risk ratio (RR, 1.3; 95% CI, 0.9 to 1.8) in myeloproliferative/myeloid malignancies
combined. The risks for any hematologic or any solid tumor were modestly but significantly
increased. Relatives of patients with MDS did not show an increased risk for any hematologic
tumors. In contrast, we found a significantly increased risk (RR, 6.5; 95% CI, 1.1 to 38.0) of
AML/MDS and of all myeloid malignancies combined (RR, 3.1; 95% CI, 1.0 to 9.8) among relatives
of patients diagnosed at younger than age 21 years.
Conclusion
We did not find evidence for familial aggregation of the severe end of the spectrum of myeloid
malignancies (AML and MDS). The risks of myeloproliferative neoplasms were modestly in-
creased with trends toward significance, suggesting a possible role of inheritance. In contrast,
although limited in sample size, relatives of young patients with AML were at increased risk of
AML/MDS, suggesting that germline genes may play a stronger role in these patients. The
increased risk of all hematologic malignancies and of solid tumors among relatives of patients with
AML suggests that genes for malignancy in general and/or other environmental factors may
be shared.
J Clin Oncol 30:179-183. © 2011 by American Society of Clinical Oncology
INTRODUCTION
Themolecular underpinnings of the development
of acute myeloid leukemia (AML) and myelodys-
plastic syndromes (MDSs) are unclear. Known
exogenous risk factors for AML include exposure
to ionizing radiation, occupational exposure to
benzeneandother chemicals, andcytotoxic chem-
otherapy, especially with alkylating agents and to-
poisomerase II inhibitors.1-5 Lifestyle factors such
as smoking, obesity, and diet may contribute to
risk.4 There is emerging evidence that autoimmune,
infectious, and inflammatory conditions are associ-
ated with an excess risk for subsequent AML or
MDS6,7suggesting that disturbances in the immune
systemmay contribute to risk.
Several single-gene syndromes are associated
with AML/MDS including bone marrow failure
syndromes, Li-Fraumeni syndrome, andDownsyn-
drome,1,7 although the various genes identified for
these syndromes do not seem to contribute to sus-
ceptibility of sporadic disease. Mutations in the
RUNX1 genehavebeendescribed in familial platelet
disorder with propensity to develop AML.8-11 Mu-
tations in CEBPA have been identified in families
with AML segregating in an autosomal dominant
pattern.8 Interestingly, somatic CEBPA mutations
are found in patients who also have germlinemuta-
tions.12 Aside from the rare syndromes identified
and rare pedigrees published with multiple patients
withAML,therearelimiteddataontheextentoffamil-
ial aggregation of AML/MDS in the population. Early
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studies found increased risk of leukemia among relatives of patientswith
all types of leukemia but this was largely accounted for by chronic lym-
phocytic leukemia (CLL).13Twostudies in theUtahPopulationdatabase
found significant familial clustering of AML, althoughCLL showed sub-
stantiallymore familial clustering.14,15
Germline genes with smaller effects may also contribute to sus-
ceptibility to AML. Since chemical exposures and radiation are asso-
ciatedwith risk ofAML, genes involved indetoxification,DNArepair,
and genome stabilization pathways could be involved. There have
been some studies of these pathways in patients with AML compared
with normals, and some associations have been found.3,16 A recent
meta-analysis of the glutathione-S-transferases found that GSTM1
andGSTT1 null genotypes were associated with risk of AML.17 How-
ever, the number of studies and genes examined are limited, and
findings have not been consistently replicated. A mutation in TERT
has also been found tobe associatedwithAMLandother hematologic
malignancies.18 Clearly, a better understanding of the role for genetic
factors in the causation of AML/MDS is of major importance for
patients and their families, health care professionals, and scientists.
Taking advantage of high-quality data from Sweden, we con-
ducted the largest population-based study to date, which included
20,579 first-degree relatives of 6,962 primary patients with AML and
3,994 first-degree relatives of 1,388 primary patients withMDS com-
pared with relatives ofmatched controls. The aim of our study was to
quantify familial aggregation for AML/MDS as well as other hemato-
poietic and solid tumors.
PATIENTS AND METHODS
Registries, Patients, Controls, and Relatives
Details of the study population have been described previously.19,20
From the Swedish Cancer Registry, we identified all patients with AML who
were diagnosed from January 1, 1958, throughDecember 31, 2004.MDSwas
not reported to theCancerRegistry until 1993, sowe included all patientswith
MDS in the Cancer Registry from January 1, 1993, through December 31,
2004.Tominimize risk forbias in this study,weexcludedpatientswithanother
cancer diagnosed before their AML or MDS diagnosis. For each patient with
AML orMDS, four population-based controls (matched by sex, year of birth,
and county of residence)were chosen randomly from the Swedish Population
database. All control individuals had to be alive at the time of AML/MDS
diagnosis for their corresponding case patient and without a hematologic
malignancy at the date of AML/MDS diagnosis for their corresponding case
patient.We obtained information from the SwedishMultigenerational Regis-
try,21 which includes information on parent-sibling-offspring relations for all
Swedish citizens who were born in the year 1932 and later, on all first-degree
relatives (parents, siblings, and offspring) of cases and controls.
The statistical approach is described in detail elsewhere.22 We classified
relatives as “affected” if they had a cancer registration with the tumor of
interest (examining up to three cancer registrations). Here, the age or age at
onset of disease in a relative is modeled by a proportional hazards model.22
Familial aggregation for each condition is evaluated by testing the hazard ratio
of being a relative of a case compared with being a relative of a control. The
model was fitted to the data by using the PHREG procedure in SAS v9.1 (SAS
Institute, Cary, NC).We used risk ratio (RR) to denote the hazard ratio, with
95% CIs provided. We adjusted for sex in all analyses. The robust sandwich
covariance matrix accounts for the dependence of the family members. We
have previously shown that the marginal model sometimes overestimates the
variance of the hazard ratio because of the matching of case and control
probands and that a bootstrap procedure can accommodate this matching.22
The bootstrap procedure was used to confirm the size of the confidence
intervals.We also tested for departure from the proportional hazards assump-
tion. Since AML occurring in young peoplemay be etiologically distinct from
the more commonly occurring AML in older adults, we also tested familial
aggregation among relatives of patients with onset in childhood through
adolescence (younger than age 21 years).
Approval for this study was obtained from the Karolinska Institutional
Review Board. Informed consent was waived because we had no contact with
study participants. An exemption from institutional review board review was
obtained from the National Institutes of Health Office of Human Subjects
Research because we used existing data without personal identifiers.
RESULTS
Atotal of 6,962patientswithAMLand1,388patientswithMDScould
be linked to first-degree relatives. These patients were matched to
27,827 and 5,312 population-based controls, respectively. As depicted
in Table 1, 53.6% of the patients with AML and 56.0% of the patients
withMDSweremale; themedian age at diagnosis was 64 years and 76
years for patients with AML orMDS, respectively.
Table 2 depicts the risk of specificmyeloid and lymphoidmalig-
nancies in 20,579 relatives of patients with AML compared with
90,406 relatives of matched controls and 3,994 relatives of patients
withMDS compared with 15,818 relatives ofmatched controls. AML
and/or MDS did not aggregate in relatives of patients with AML
orMDS.
Myeloproliferative neoplasms (MPNs) showed a modest in-
crease among relatives of patients with AML, which was mostly ac-
counted for by the increased risk of polycythemia vera. The
combinationof allMPNs and allmyeloidmalignancieswas alsomod-
estly increased although not significant. Lymphoid malignancies
showed a modest but nonsignificant increased risk in relatives of
patients with AML with a borderline significantly increased risk of
CLL. The risk for “any hematologic malignancy” was significantly
increased among relatives of patients with AML (RR, 1.2; 95%CI, 1.0
Table 1. Characteristics of Primary Patients With AML or MDS and Matched
Controls With Available Relatives
Variable
AML
(n  6,962)
Controls
(n  27,827)
MDS
(n  1,388)
Controls
(n  5,312)
No. % No. % No. % No. %
Median age at diagnosis,
years 64 76
Males 53.6 54.0 56.0 55.2
Age group, years
 21 534 7.7 14 1.0
21-39 722 10.4 19 1.4
40-49 674 9.7 30 2.2
50-59 950 13.6 100 7.2
60-69 1,555 22.3 233 16.8
70-79 1,672 24.0 532 38.3
 80 855 12.3 460 33.1
Year of diagnosis
 1976 949 13.6 0
1976-1985 1,638 23.5 0
1986-1995 2,388 34.3 300 21.6
1995-2004 1,987 28.6 1,088 78.4
Abbreviations: AML, acute myeloid leukemia; MDS, myelodysplastic syndrome.
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to 1.4). The risk for “any solid tumor” was also significantly increased
(RR, 1.1; 95%CI, 1.0 to 1.1).However, bothof these increased relative
risks were modest and the significance levels were borderline. First-
degree relatives of patients with MDS had no significantly increased
risk of any malignancy, but the sample size was smaller than that for
the AML analysis. The risk of MDS appears to be higher, but the
number of affected relatives is so small that no conclusions can be
made. Aswith theAML sample, the risk of solid tumorswasmodestly
increased (RR, 1.1; 95%CI, 1.0 to 1.2).
Table 3 details the risks in relatives of younger patients (diag-
nosed before age 21 years) compared with relatives of controls.
Although numbers were small (1,951 relatives of patients with
AML compared with 9,790 relatives ofmatched controls), relatives
of these younger patients with AML had a significantly increased
risk of all AML/MDS and a three-fold (and significantly) increased
risk for all myeloid malignancies combined. Among lymphoid
malignancies, there was a significantly increased risk of multiple
myeloma, but the numbers were small. The risks for “any hemato-
logic malignancy” and “any solid tumor” were modestly but non-
significantly increased.
Finally, we tested the validity of the assumption of proportional
hazards by introducing interaction terms of the main effects with the
time-dependent age variable. None of these interaction terms were
statistically significant, indicating that the application of the propor-
tional hazards model was valid in our study. In addition, applying a
bootstrapproceduremade littledifference in the sizeof the confidence
intervals anddid not change any conclusions about the significance of
the risk estimates.
DISCUSSION
Many patients worry about their familymembers having a potentially
increased risk of developing AML or MDS and, on the basis of our
clinical experience, many clinicians are of the opinion that there is a
small but significant familial pathogenic component. In this largest
population-based study to date, including all age groups of patients
with AML or MDS, we found no significant familial aggregation for
AML or MDS. We found a small increased risk of MPNs (which was
significant for polycythemia vera only) and of all myeloid disorders
combined, but the increased risk did not reach statistical significance.
However, given the size of the risks and the trend toward significance,
we cannot rule out a small role for inherited factors indetermining the
risk for myeloid disorders. There was also a small increased risk for
lymphoid malignancies which was not significant, except for CLL.
Relatives of patients with AML were at a modest but statistically
significant increased risk for “any hematologic malignancy.” The risk
for “any solid tumor” was also significantly increased. Relatives of
patients with MDS showed similar trends for myeloid malignancies
but the sample size was much smaller and the risks were not signifi-
cantly increased. However, the risk of solid tumors was modestly
increased and borderline significant.
The absence of increased risk for the most severe malignancies,
AML and MDS, among relatives and the modest increased risks for
Table 2. Risk of Myeloid, Lymphoid, and Solid Malignancies in Relatives of Patients With AML or MDS
Outcome in Relatives
AML
(n  20,579)
Controls
(n  90,406) RR 95% CI
MDS
(n  3,994)
Controls
(n  15,818) RR 95% CI
Myeloid
AML 15 70 0.9 0.5 to 1.9 3 11 1.1 0.30 to 3.8
MDS 4 10 1.8 0.6 to 5.7 2 2 4.0 0.4 to 43.1
AML/MDS 19 80 1.0 0.6 to 1.9 5 13 1.5 0.5 to 4.8
CML 9 29 1.3 0.6 to 2.9 1 2 2.0 0.2 to 21.6
Any myeloid malignancy 28 109 1.1 0.7 to 1.8 6 15 1.6 0.6 to 4.5
PV 13 25 2.3 1.2 to 4.5 1 5 0.8 0.1 to 6.7
ET 5 22 1.0 0.4 to 2.6 0 3
MF 4 17 1.0 0.4 to 3.1 1 3 1.3 0.1 to 12.6
MPD NOS 3 12 1.1 0.3 to 3.9 2 0
Any myeloproliferative malignancy† 25 75 1.5 0.9 to 2.3 4 10 1.6 0.50 to 5.0
Any myeloid or myeloproliferative malignancy 53 182 1.3 0.9 to 1.8 10 24 1.6 0.7 to 3.6
Lymphoid
NHL 67 287 1.0 0.8 to 1.3 8 46 0.7 0.3 to 1.4
CLL 25 70 1.6 1.0 to 2.5 2 16 0.5 0.1 to 2.1
HL 20 64 1.3 0.8 to 2.2 2 10 0.8 0.2 to 3.6
MM 26 117 1.0 0.6 to 1.5 4 23 0.7 0.2 to 2.0
Any lymphoproliferative malignancy 140 539 1.1 0.9 to 1.4 16 95 0.7 0.4 to 1.1
ALL 7 26 1.2 0.5 to 2.7 1 2 2.0 0.2 to 21.3
Any hematologic malignancy 197 742 1.2 1.0 to 1.4 27 120 0.9 0.6 to 1.3
Any solid tumor 2,087 8,476 1.1 1.0 to 1.1 381 1,412 1.1 1.0 to 1.2
NOTE. Bolded entries indicate that risk ratio (RR) is significantly different from 1.0.
Abbreviations: ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; ET, essential
thrombocythemia; HL, Hodgkin’s lymphoma; MDS, myelodysplastic syndrome; MF, myelofibrosis; MM, multiple myeloma; MPD, myeloproliferative disorder; NHL,
non-Hodgkin’s lymphoma; NOS, not otherwise specified; PV, polycythemia vera.
Any myeloid malignancy includes AML, MDS, and CML.
†Any myeloproliferative malignancy includes PV, ET, MF, and MPD NOS.
‡Any lymphoproliferative malignancy includes NHL, HL, CLL, and MM.
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combined myeloproliferative and myeloid malignancies can be con-
trasted with previous findings of ours from the same population
showing highly increased risks for other lymphoid malignancies23-26
and for myeloproliferative neoplasms27 among relatives with those
conditions. The increased risk tofirst-degree relatives ranged from2.0
to eight-fold or more depending on the particular subgroups ana-
lyzed. In fact, relatives of patients with MPNs had a more than five-
fold increased risk for MPNs compared with relatives of controls.27
The sample sizes in many of these other studies are similar to our
sample size of patients with AML and their relatives in this study,
making lack of power an unlikely possibility for explaining the failure
to find an increased risk of AML/MDS in relatives.
Interestingly, we found significant familial aggregation patterns
among first-degree relatives of young (age 21 years) patients with
AML compared with their matched controls. Despite the much
smaller sample sizes, first-degree relatives of these younger patients
had significantly increased risks for AML/MDS as well as a three-fold
risk for any myeloid malignancy. They were also at borderline in-
creased risk for any lymphoid malignancy, and the risk of multiple
myeloma was significantly increased. The risks for “any hematologic
malignancy” and “any solid tumor”were similar to those of thewhole
sample of AML relatives but were not significantly increased.
In summary, our findings suggest that, overall, there is not a
strong specific genetic predisposition to AML or MDS. The modest
increase in risk of MPNs, all myeloid malignancies combined, and
“any hematologicmalignancy” suggests that relativesmay share some
germline genes predisposing them to hematologic malignancies in
general or even malignancy in general, given the increased risk for
“any solid tumor.”One could argue that findingmore solid tumors in
relatives of patients with AML and MDS might be due to increased
surveillance in relatives because of the diagnosis of the index case.
When we tested for increased risk of solid tumors in relatives of
patients with AML restricted to only those tumors that occurred
before the AML diagnosis of the index case, the risk was unchanged.
We also examined the risk of all solid tumors combined in relatives of
patients with other hematologic malignancies (specifically CLL, mul-
tiple myeloma, non-Hodgkin’s lymphoma, and Hodgkin’s lym-
phoma) that we have previously reported and found that they were
also modestly but significantly increased (data not shown). Thus, the
modest increase in solid tumors among relatives of patientswithAML
may not be specific to AML since we see it in other hematologic
malignancies. The underlying causes may be shared etiologic factors
(including germline susceptibility genes and environmental expo-
sures) that affect the risk of nonspecific cancer, and there may also be
an effect of increased surveillance or it may be a combination of these
factors. Future studies are needed to characterize underlying mecha-
nisms of our findings.
On the basis of small numbers, we found evidence of familial
aggregation of AML/MDS as well as combined categories of tumors
among first-degree relatives of patients with AML who were diag-
nosed when they were younger than age 21 years, which supports the
existence of genes with stronger effects that predispose to AML/MDS
susceptibility in the young. Since this subgroup was small, further
studies are needed to confirm this stronger association among
young patients.
Recent candidate gene studies have identified potential associa-
tions of gene variants with AML and more will be identified as high
throughput genotyping methods are applied to AML andMDS pop-
ulations. Sequencing of tumors has also allowed identification of so-
matic genetic changes in AML and related malignancies which may
also provide clues to the germline genes involved.28 The observed
differences by age provide additional support that there may be age-
related etiologic/molecular heterogeneity in AML/MDS.
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Table 3. Risk of Myeloid, Lymphoid, and Solid Malignancies in Relatives
of Patients With AML Diagnosed at Age 20 Years or Younger
Outcome
in Relatives
AML
(n  1,951)
Controls
(n  9,790) RR 95% CI P
Myeloid
AML 3 0 .005
MDS 0 2
AML/MDS 3 2 6.5 1.1 to 38.0
CML 2 5 1.8 0.3 to 9.0
Any myeloid malignancy 5 7 3.1 1.0 to 9.8
Any myeloproliferative
malignancy† 1 3 1.5 0.2 to 14.3
Any myeloid or
myeloproliferative
malignancy 6 10 2.6 1.0 to 7.2
Lymphoid
NHL 5 20 1.0 0.4 to 2.7
CLL 3 4 3.6 0.8 to 16.5
HL 1 7 0.6 0.1 to 5.2
MM 4 4 4.3 1.1 to 16.9
Any lymphoproliferative
malignancy‡ 13 35 1.6 0.8 to 2.9
ALL 0 4
Any hematologic malignancy 18 49 1.6 0.9 to 2.6
Any solid tumor 151 607 1.1 0.9 to 3.2
NOTE. Bolded entries indicate that risk ratio (RR) is significantly different
from 1.0.
Abbreviations: ALL, acute lymphocytic leukemia; AML, acute myeloid leuke-
mia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; HL,
Hodgkin’s lymphoma; MDS, myelodysplastic syndrome; MM, multiple mye-
loma; NHL, non-Hodgkin’s lymphoma.
Any myeloid malignancy includes AML, MDS, and CML.
†Any myeloproliferative malignancy includes polycythemia vera, essential
thrombocythemia, myelofibrosis, and myeloproliferative disorder.
‡Any lymphoproliferative malignancy includes NHL, HL, CLL, and MM.
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